SynthesisEuropean journal of clinical pharmacology2026
A systematic review and meta-analysis of exposure-response analysis of osimertinib in patients with non-small-cell lung cancer.
Synthesis in European journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeOsimertinib displays substantial inter-individual variability in both pharmacokinetics and pharmacodynamics. This study aimed to explore the exposure-response relationship of osimertinib, thereby to provide a basis for personalized therapeutic strategies.
methodsWe systematically searched PubMed, Embase, the Cochrane Library, China National Knowledge Infrastructure, Wanfang Database, and China Biology Medicine Literature Database separately through October 2024, with no study type restrictions. The Newcastle-Ottawa Scale was used for quality assessment, and data were extracted and recorded using Excel software. The meta-analysis was conducted using Stata software.
resultsA total of nine observational studies were included. Among them, five studies identified a correlation between steady-state trough concentration and progression-free survival, with three specifically demonstrating that the low steady-state trough concentration group had longer progression-free survival. One study observed a negative correlation between clearance and overall survival via Cox proportional hazards regression. Additionally, several studies reported correlations between exposure and adverse events, though conclusions varied substantially across studies.
conclusionMultiple studies demonstrated that lower osimertinib steady-state trough concentration correlated with longer progression-free survival in Non-Small-Cell Lung Cancer, challenging the conventional assumption that higher drug exposure directly translates to superior efficacy. No consistent overall survival association exists. The relationships of adverse events remain unclear due to inconsistent study outcomes. These findings highlight the need for personalized dosing strategies through further research.
Indexed as
Identifiers
41917247What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.